|Bid||118.17 x 800|
|Ask||118.16 x 900|
|Day's range||116.38 - 119.06|
|52-week range||74.75 - 139.55|
|Beta (5Y monthly)||1.22|
|PE ratio (TTM)||129.60|
|Earnings date||07 Feb 2024 - 12 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||125.65|
SAN DIEGO, December 06, 2023--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world’s most accurate1,2 CGM system.
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.
Michael Brown, the Executive Vice President and Chief Legal Officer of DexCom Inc, has recently sold 3,612 shares of the company's stock.